🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Abeona Therapeutics Inc. ABEO R2KPHARMA

Healthcare · Biotechnology · United States
https://www.abeonatherapeutics.com
Company Profile ↓
$6.00
-8.54% 1Y
Mkt Cap$341.97M
P/E6.32
P/B2.84
52W High$7.46
52W Low$4.17
Book Value$2.55
EPS (TTM)$0.95

Company Overview

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 71.0%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 39.5%.

Consistent Profit Growth

Net profit has compounded at 93.1% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 60.3% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 6.3, below the sector median of 25.2.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.16.

Recent Developments

  • 5-Year Trend Long-term compounding — revenue CAGR 60.3%, profit CAGR 93.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:60.26%
1 Year:-

Compounded Profit Growth

5 Years:93.11%
1 Year:-

Stock Price Performance

1 Year:-8.54%
6 Months:+23.71%
3 Months:+9.89%
1 Month:-13.04%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 56% of range
$4.17 $7.46
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)44.32 · Neutral
Price Performance
1M-13.04%
3M+9.89%
6M+23.71%
1Y-8.54%
Valuation vs Sector

P/E of 6.32 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 71.0%.
  • Healthy ROCE of 39.5%.
  • Compounding revenue at 60.3% over 5 years.
  • Profit CAGR of 93.1% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
6.32
Industry PE
25.17
Forward P/E
20.93
PEG Ratio
-
Book Value
$2.55
Price to Book
2.84
P/S
28.32
EV/EBITDA
-2.97
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
60.26%
Profit 5Y
93.11%
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
39.49%
ROE
70.99%
ROA
-38.92%
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.30
EPS (TTM)
$0.95

Balance Sheet & Liquidity

Debt/Equity
0.16
Quick Ratio
5.64
Current Ratio
5.89
Debt
$23.17M
Total Assets
$198.49M
Current Assets
$182.99M
Working Capital
$175.34M

Ownership

Promoter Holding
16.49%
Chg in Prom Hold
-0.05%
FII / Inst Holding
69.74%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$341.97M
Total Revenue (TTM)
$14.54M
EBITDA
$-90.05M
Free Cash Flow
$-56.59M
Operating Cash Flow
$-77.73M
Shares Outstanding
57.00M
Gross Margin
-
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ABEO Abeona Therapeutics Inc. R2KPHARMA 6.00 6.32 $341.97M 0.00% 39.49% 70.99% 60.26% 93.11%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -------------1.71M-------7.00M---346.00K1.00M--3.50M-----0400.00K05.42M8.72M
Cost of Revenue -----------------------------------0100.00K488.00K2.84M2.70M
Gross Profit -----------------------------------0300.00K-488.00K2.58M6.02M
Operating Expenses -----------------------------------19.73M23.09M23.53M25.49M29.06M
Operating Income -633.00K-2.00M-4.13M-6.16M-6.16M-6.71M-5.17M-5.28M-8.44M-5.36M-8.75M-10.68M-12.56M-16.92M-18.01M-19.05M-23.98M-17.65M-16.41M-48.21M-12.48M-6.25M-14.60M-13.71M-14.87M-20.59M-8.01M-9.38M-12.04M-10.55M-11.33M-14.33M-17.86M---19.73M-22.79M-24.02M-22.91M-23.03M
EBITDA ------------------------------------10.22M126.07M-18.57M-18.70M-15.37M
Interest Expense -----------------------------------998.00K957.00K901.00K884.00K830.00K
Pretax Income ------------------------------------12.03M124.34M-20.36M-20.68M-17.07M
Tax Provision -----------------------------------015.51M-15.20M-215.00K2.00K
Net Income -1.47M-2.00M-4.11M-6.07M-5.54M-6.70M-2.62M-5.25M-8.28M-5.34M-8.45M-10.53M-12.24M-16.42M-17.48M-18.55M-23.92M-17.37M-16.43M-48.16M-13.01M-7.24M-16.00M-15.21M-7.04M-22.04M-4.10M-6.43M-9.11M-16.65M-11.84M-31.58M7.41M---12.03M108.83M-5.16M-20.46M-17.07M
Diluted EPS -4.15-------------------------1.36-1.00-0.54-0.92-0.48-1.16-0.26-0.63--0.241.71-0.10--0.30
R&D Expense 73.00K453.00K610.00K1.58M1.85M3.02M2.75M2.20M5.81M3.28M5.71M8.16M7.92M13.15M9.47M11.74M16.31M10.92M9.61M6.82M6.11M7.97M8.32M8.53M9.06M10.54M6.66M5.49M8.04M8.52M7.15M7.21M9.22M8.94M-9.94M5.94M4.22M-9.55M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 481.00K1.84M4.40M2.04M925.00K1.04M889.00K837.00K3.00M-10.00M-1.41M3.50M05.82M
Cost of Revenue ------------450.00K1.60M03.42M
Gross Profit ------------964.00K1.90M02.40M
Operating Expenses ------------46.22M50.09M64.21M91.84M
Operating Income -7.76M-7.88M-4.32M-3.80M-3.13M-18.55M-23.88M-27.84M-58.17M-77.09M-81.42M--45.26M-48.20M-64.21M-89.45M
EBITDA -------------34.38M-50.57M-56.62M78.59M
Interest Expense ------------736.00K418.00K4.21M3.74M
Pretax Income -------------39.70M-54.19M-63.73M71.28M
Tax Provision --------------0100.00K
Net Income -7.54M-2.53M-10.53M4.45M-26.78M-14.53M-21.87M-27.32M-56.67M-76.28M-84.23M--39.70M-54.19M-63.73M71.18M
Diluted EPS ---0.523.04-15.26--------5.53-2.53-1.551.01
R&D Expense 3.35M3.58M2.01M884.00K333.00K4.71M10.65M16.99M38.70M48.57M30.14M38.73M28.96M31.09M34.36M26.81M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Jan 2018Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -8.77M3.79M1.73M613.00K16.58M80.06M111.06M178.77M-174.40M223.38M151.20M-64.21M64.00M108.93M219.57M
Current Assets --------------53.10M55.74M100.85M204.91M
Cash & Equivalents 607.00K7.03M2.46M396.00K424.00K11.52M40.14M69.14M137.75M-18.75M129.26M12.60M-14.22M14.47M23.36M78.44M
Inventory ----------------05.49M
Receivables -------------3.00M0-06.15M
Total Liabilities -29.57M21.39M18.81M15.39M11.77M12.33M11.96M8.67M2.39M40.35M44.95M48.65M-37.45M49.18M64.90M60.35M
Current Liabilities -14.26M12.19M6.63M8.96M2.90M1.48M8.30M5.61M2.39M20.35M38.70M41.96M-7.78M13.42M16.59M29.57M
Long Term Debt ----------------13.04M7.81M
Total Debt --------------7.63M5.40M23.05M24.97M
Total Equity --20.80M-17.61M-17.08M-14.78M4.82M67.72M99.10M170.10M6.30M134.04M178.43M102.55M-26.76M14.83M44.03M159.22M
Shares Outstanding --------------17.72M26.52M45.64M55.04M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -6.86M-7.61M-3.96M1.00K---13.01M-22.66M-39.11M-62.82M-35.02M--43.48M-37.01M-56.02M-76.33M
Investing Cash Flow -7.00K-40.00K-13.00K-2.00K---519.00K-860.00K-85.09M59.98M-83.71M--23.96M208.00K-39.24M105.03M
Financing Cash Flow 13.29M3.08M1.90M29.00K--42.54M92.40M5.48M113.90M1.94M-43.17M37.06M104.14M26.04M
Capital Expenditure -7.00K-40.00K-13.00K-2.00K-0-308.00K-519.00K-860.00K-9.24M-6.31M-1.34M--130.00K-331.00K-2.45M-7.97M
Free Cash Flow -6.87M-7.65M-3.97M-1.00K---13.53M-23.52M-48.35M-69.13M-36.35M--43.61M-37.34M-58.46M-84.30M
Net Change in Cash -------------24.27M256.00K8.88M54.74M

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------------68.2%54.1%-41.2%
Operating Margin % -1,612.7%-428.3%-98.0%-186.3%-338.5%-1,783.3%-2,686.3%-3,325.7%-1,940.2%--814.2%--3,200.6%-1,377.1%--1,536.9%
Net Margin % -1,566.9%-137.7%-239.1%217.9%-2,894.9%-1,396.7%-2,460.4%-3,263.9%-1,890.3%--842.3%--2,807.4%-1,548.2%-1,223.1%
ROE % 36.2%14.4%61.7%-30.1%-556.0%-21.4%-22.1%-16.1%-42.3%-42.8%-82.1%--148.3%-365.5%-144.7%44.7%
ROCE % 141.4%93.7%88.1%45.6%-22.9%-23.6%-23.2%-16.1%-37.8%-41.7%-74.5%--80.2%-95.3%-69.5%-47.1%

Shareholding Pattern

Insiders
16.49%
Institutions
69.74%
Public Float
83.51%

Top Institutional Holders

#Holder% HeldSharesValue
1 Nantahala Capital Management, LLC 8.98% 5.14M $30.41M
2 Blackrock Inc. 5.86% 3.35M $19.85M
3 Cable Car Capital, LP 5.26% 3.01M $17.80M
4 AIGH Capital Management LLC 5.22% 2.99M $17.68M
5 Vanguard Capital Management LLC 3.87% 2.21M $13.09M
6 OneDigital Investment Advisors LLC 2.89% 1.65M $9.79M
7 AWM Investment Company, Inc. 2.60% 1.49M $8.80M
8 Geode Capital Management, LLC 2.21% 1.26M $7.47M
9 Kennedy Capital Management, LLC 2.17% 1.24M $7.34M
10 Goldman Sachs Group Inc 2.14% 1.22M $7.25M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ABEO

Yahoo Finance Wed, 02 Sep 2026

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026: Cantor Global Healthcare Conferen…

Yahoo Finance ue, 01 Sep 2026

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nas…

Yahoo Finance Mon, 17 Aug 2026

Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ...

Despite manufacturing hiccups and patient cancellations, the company expands its treatment center network and secures CMS NTAP status to bolster market access.

Yahoo Finance Mon, 17 Aug 2026

ABEO: Zevaskyn® Launch Gains Momentum

By David Bautz, PhD NASDAQ: ABEO READ THE FULL ABEO RESEARCH REPORT Business Update Five Patients Treated in 2Q26; 12 Patients Treated in Total Thus Far Abeona Therapeutics, Inc (NASDAQ: ABEO) is continuing the commercial launch of Zevaskyn…

Yahoo Finance hu, 13 Aug 2026

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments completed – - Expanding QTC network now i…

Yahoo Finance hu, 06 Aug 2026

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company will host a conference call on Thursday, August 13, 2026 at 8:30 a.m. ET to discuss its financial results for the second q…

ABEO — Frequently Asked Questions

What is the current share price of Abeona Therapeutics Inc. (ABEO)?

As of 2026-09-07 16:24 PDT, Abeona Therapeutics Inc. (ABEO) trades at $6.00 on NasdaqCM. Its 52-week range is $4.17 to $7.46.

What is the market capitalisation of ABEO?

Abeona Therapeutics Inc. (ABEO) has a market capitalisation of $341.97M on NasdaqCM.

What is the P/E ratio of ABEO?

ABEO trades at a trailing price-to-earnings (P/E) ratio of 6.32. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.84.

What is the return on equity (ROE) of ABEO?

ABEO has a return on equity (ROE) of 70.99%. Its return on capital employed (ROCE) is 39.49%.

Is ABEO a good stock to buy?

This page provides a data-driven analysis of Abeona Therapeutics Inc. (ABEO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space